- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.05. | SAB Biotherapeutics reports Q1 results | 2 | Seeking Alpha | ||
| 09.05. | SAB Biotherapeutics, Inc.: SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates | 220 | GlobeNewswire (Europe) | MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB BIO" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human... ► Artikel lesen | |
| 09.05. | SAB Biotherapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 03.04. | SAB Biotherapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| SAB BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 01.04. | SAB Biotherapeutics stock holds $6 target with Buy rating | 2 | Investing.com | ||
| 31.03. | SAB Biotherapeutics reports FY results | 3 | Seeking Alpha | ||
| 31.03. | SAB Biotherapeutics, Inc.: SAB BIO Reports Full Year 2024 Operating and Financial Results | 264 | GlobeNewswire (Europe) | MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB BIO" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human... ► Artikel lesen | |
| 05.02. | SAB Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 28.01. | Why Is SAB BIO Stock Trading Lower On Tuesday? | 6 | Benzinga.com | ||
| 28.01. | Pre-market Movers: IMAC Holdings, Planet Image International, SAB Biotherapeutics, MicroCloud Hologram, Avalon Holdings | 723 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.30 A.M. ET).In the Green IMAC Holdings, Inc. (BACK) is up over 91% at $1.59.
Planet... ► Artikel lesen | |
| 28.01. | SAB Biotherapeutics, Inc.: SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142 | 411 | GlobeNewswire (Europe) | SAB-142 was generally well-tolerated among healthy volunteers; data from Phase 1 trial confirms SAB-142 does not cause serum sickness or anti-drug antibodies at target dose Study results support... ► Artikel lesen | |
| 28.01. | SAB Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 23.01. | SAB Biotherapeutics, Inc.: SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy | 4 | GlobeNewswire (USA) | ||
| 06.01. | Here's Why SAB Biotherapeutics, Inc. (NASDAQ:SABS) Is Among the Best Diabetes Stocks to Buy Under $10 | 1 | Insider Monkey | ||
| 06.11.24 | SAB Biotherapeutics, Inc.: SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update | 195 | GlobeNewswire (Europe) | Company announced completed Phase 1 enrollment for SAB-142 with no observation of serum sickness. The company remains on track for a topline Phase 1 data readout by the end of the year. MIAMI, Nov.... ► Artikel lesen | |
| 08.08.24 | SAB Biotherapeutics, Inc.: SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates | 259 | GlobeNewswire (Europe) | FDA provided clearance to SAB's IND Appointed Lucy To as Chief Financial Officer Announced founding of a new Clinical Advisory Board MIAMI, Aug. 08, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS)... ► Artikel lesen | |
| 05.08.24 | SAB Biotherapeutics, Inc.: SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes | 597 | GlobeNewswire (Europe) | MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS) (the "Company" or "SAB"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing... ► Artikel lesen | |
| 31.07.24 | SAB Biotherapeutics, Inc.: SAB BIO Appoints Lucy To as Chief Financial Officer | 186 | GlobeNewswire (Europe) | MIAMI, July 31, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is... ► Artikel lesen | |
| 20.06.24 | SAB Biotherapeutics, Inc.: SAb Biotherapeutics Rebrands as SAB BIO | 256 | GlobeNewswire (Europe) | New name, logo and website updates, stock symbol will remain SABS With new brand identity, SAB BIO continues drive towards serious unmet needs in type 1 diabetes MIAMI, June 20, 2024 (GLOBE NEWSWIRE)... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 99,10 | +1,64 % | BioNTech: Milliardendeal mit Bristol Myers Squibb - Aktie schießt ins Plus | BioNTechs Aktien schießen in der US-Vorbörse am Montag regelrecht nach oben: Aktuell werden 106,10 Dollar notiert nach einem NASDAQ-Schlusskurs bei 95,81 Dollar vom Freitag. Der Grund für den Kursanstieg... ► Artikel lesen | |
| CUREVAC | 3,980 | +2,00 % | CureVac mit SPEZIAL-MELDUNG: Insider kaufen massenhaft Anteile - Das dürfen Sie nicht verpassen! | ||
| AMGEN | 252,35 | +0,34 % | Amgen Says Imdelltra Cut Risk Of Death By 40% In Small Cell Lung Cancer Patients | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN) Monday announced positive interim results from the Phase 3 DeLLphi-304 study showing Imdelltra reduced the risk of death by 40% and significantly... ► Artikel lesen | |
| NOVAVAX | 6,251 | -0,16 % | Schock-News für Novavax Anleger vor dem Wochenende: So müssen Sie heute noch auf diese Sondermeldung reagieren! | ||
| BIOGEN | 115,80 | +0,17 % | DAX tritt auf der Stelle - Nvidia & Biogen mit Überraschung! Gold, EUR & Aktien im Chartcheck | ||
| MAINZ BIOMED | 2,775 | -100,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed gibt Interim-Ergebnisse seiner klinischen Studie eAArly DETECT 2 bekannt | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed gibt Interim-Ergebnisse seiner klinischen Studie eAArly DETECT 2 bekannt
16.05.2025 /... ► Artikel lesen | |
| VIKING THERAPEUTICS | 23,800 | +0,63 % | Could Viking Therapeutics Become the Next Eli Lilly? | ||
| INTELLIA THERAPEUTICS | 6,774 | +0,83 % | Canaccord Genuity lowers Intellia stock price target to $54 | ||
| BIOCRYST PHARMACEUTICALS | 9,610 | -0,52 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
| TEMPUS AI | 54,68 | -0,62 % | XFRA NEW INSTRUMENTS AVAILABLE ON 03.06.2025 | The following instruments on XETRA do have their first trading 03.06.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 03.06.2025
Aktien
1 US88023B1035 Tempus AI Inc.
2 KYG9482E1180... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 34,950 | +0,81 % | FDA Grants Platform Technology Status To Sarepta's RAAVrh74 Vector | WASHINGTON (dpa-AFX) - Sarepta Therapeutics (SRPT), Wednesday announced that the FDA has designated its rAAVrh74 viral vector used in the investigational gene therapy SRP-9003 for limb-girdle... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,300 | +2,52 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders | Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory... ► Artikel lesen | |
| EXELIXIS | 37,860 | +2,32 % | Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell? | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 0,890 | -0,63 % | PacBio Board Independent Investigation Concludes Allegations Unsubstantiated | MENLO PARK, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced that the Special Committee of its Board of Directors (the "Special Committee") has concluded its independent... ► Artikel lesen | |
| VAXART | 0,341 | -3,78 % | Vaxart, Inc.: Vaxart Announces Adjournment of Annual Meeting of Stockholders |
SAB BIOTHERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,860 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SAB BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.